In 2005, Baxter et al. [3] first found that the rate of JAK2 gene mutations in BCR/ABL negative MPN was up to more than 50%, and the rate of JAK2 mutations in PV patients was greater than 90%, which was strongly associated with the occurrence and development of MPN. Here, ABL1 is linked to myeloproliferative neoplasm.